[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-associated-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-associated-cancers":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,105,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100639699","phase-1-combining-neo-adjuvant-atr-inhibition-with-nodal-sbrt-for-early-stage-resectable-hpv-opsccs-100639699",false,"NCT07578467","Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs","A Phase Ib\u002FII Study Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs","Inclusion Criteria:\n\n* Age ≥ 18\n* Patients that have been diagnosed with HPV-positive throat cancer (OPSCC) at an early stage (stage I or II), confirmed by a biopsy.\n* Patients' blood calcium level is within a safe range\n* Patients' blood, kidney, and liver health are strong enough, shown through specific medical test results\n* If a participant is female, she must not be pregnant or breastfeeding.\n* If a participant is male, he must agree to use highly effective birth control from the start of the study until a short period after the last dose of the study drug.\n\nExclusion Criteria:\n\n* Patients with late-stage tumors (Stage III or IV)\n* If the cancer has already spread to distant parts of the body (M1) when first diagnosed\n* Prior advanced head and neck cancer requiring radiation or major surgery\n* Patients whose original tumor site cannot be identified\n* Patients that have a known additional malignancy that is progressing or requires active treatment\n* Patients that had a surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119. This does not include procedures that are used to diagnose or determine extent of study disease (such as biopsies).\n* Patients taking medications that strongly affect how the body processes certain drugs (CYP enzymes) at the same time as the study treatment.\n* Patients with active infections and\u002For receiving systemic antibiotics or anti-viral medications.\n* Patients with uncontrolled HIV or active hepatitis B or C are usually not eligible. However, those whose infections are well-controlled on treatment for at least a month and meet certain viral load limits can participate\n* Current or past diagnosis of leukemia within the past 5 years.\n* Patients with a history of non-malignant gastrointestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.\n* Patient has uncontrolled hypertension at time of enrollment.\n* Patients who recently had serious kidney problems or kidney disease.\n* Patients cannot have taken another experimental drug within 30 days-or within a period equal to five times that drug's half-life-before starting this study\n* Medical illness that, in the opinion of the Investigator, may impact the safety of the patient\n* Patients who use recreational drugs or have mental health conditions that might make it hard to follow study visits, based on the doctor's judgment.\n* Known hypersensitivity to ATRN-119 or its ingredients\n* Patients with serious liver disease or liver problems that could affect how the body processes the study drug\n* Patients who are fairly limited in daily activities (ECOG score of 2 or higher)\n* Patients with serious other health problems that the doctor thinks could prevent them from completing the study\n* Pregnancy or lactation\n* Inability to provide informed consent","ALL","18 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat early-stage throat cancer that is caused by HPV.\n\nThe goal of this study is to treat cancer effectively while reducing side effects and helping patients maintain a better quality of life over the long term. Researchers hope that this approach will be just as successful-or possibly more successful-than current treatments, which already have high cure rates.\n\nParticipants will:\n\n* Take 800mg of ATRN-119 every day for 10 days\n* Receive 1 treatment (called a \"fraction\") of SBRT to the neck on day 3 of ATRN-119 dosing.\n* Keep a short diary to track ATRN-119 dosing. The diary will be provided by study team\n* Receive standard of care treatment after treatment with ATRN-119 + SBRT including TransOral Robotic Surgery (TORS) to remove the primary tumor with Neck Dissection and adjuvant therapy (if indicated)\n* Receive additional safety checkups and tests by researchers during routine visits with their cancer doctor for 2 years after study treatment",[27,28,29,30,31],"HPV Positive Oropharyngeal Squamous Cell Carcinoma","Squamous Cell Carcinoma","HPV (Human Papillomavirus)-Associated Carcinoma","HPV Associated Cancers","Oropharyngeal HPV Squamous Cell Carcinoma","NOT_YET_RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":20},"2026-05-31",{"date":40,"type":20},"2030-05-31",{"name":42,"class":43},"Abramson Cancer Center at Penn Medicine","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100638783","testing-the-feasibility-of-different-hpv-screening-and-care-strategies-for-women-living-with-hiv-100638783","NCT07576842","Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV","CASCADE: A Feasibility Study of HPV Screening and Management Strategies Utilizing Extended Molecular HPV DNA Genotyping and HPV Viral Load in Women Living With HIV","Inclusion Criteria:\n\n* HIV-1 infection, as documented by:\n\n  1. any FDA-approved, licensed HIV rapid test performed in conjunction with screening (oral immunoblot, ELISA test kit, and confirmed by Western blot or other approved test), OR\n  2. a physician's written record that documents HIV infection with supporting information on the participant's relevant medical history and\u002For current management of HIV infection, OR\n  3. documentation of a prescription of an approved antiretroviral regimen by either possession of pill bottles or packages with prescriber's name or ARVs dispensed from an HIV clinical treatment program with participant identifiers affixed to the bottles or packages.\n* Aged 25 or older.\n* Ability to understand and the willingness to sign a written informed consent document by the participant or by the legal representative(s) of the participant.\n* Have an intact cervix.\n\nExclusion Criteria:\n\n* Current symptoms or concern for cervical cancer.\n* History of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer or current symptoms of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer.\n* Have undergone cervical hHSIL treatment in the past year.\n* Have a history of hysterectomy with removal of the cervix.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including opportunistic infections of AIDS and\u002For genitourinary infections), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any other medical condition or social situation that would put the participant, the study staff, or the study outcomes at risk, as determined by the site investigators.","FEMALE","25 Years",{"count":54,"type":20},750,[56],"NA","The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and\u002For 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16\u002F18) are not well defined.\n\nThis prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at Month 6 for repeat evaluation.\n\nThe study will evaluate feasibility for a future trial by examining recruitment, retention, return for evaluation, and completion of treatment. It will also explore management strategies for women with non-16\u002F18 hrHPV based on extended genotyping and HPV viral load compared to standard of care approaches using visual inspection with acetic acid (VIA).",[59,30,60,61,62],"Human Papillomavirus (HPV)","Cervical Cancer","Human Immunodeficiency Virus (HIV)","Cervical Intraepithelial Neoplasia (CIN)","2026-05-04",{"date":65,"type":36},"2026-05-08",{"date":67,"type":20},"2026-06-01",{"date":69,"type":20},"2027-06-01",{"name":71,"class":43},"University of California, San Diego",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":51,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":72},"100619536","emergency-department-based-cervical-cancer-screening-through-self-sampling-100619536","NCT07345897","Emergency Department-based Cervical Cancer Screening Through Self-sampling","Advancing Cervical Cancer Screening Through Emergency Department-based Self-Sampling","Inclusion Criteria:\n\n* Cisgender women and transgender\u002Fnon-binary individuals with a cervix,\n* Age 30 - 65 years, and demonstrating decisional capacity to consent to participate with no known exclusion criteria present.\n\nExclusion Criteria:\n\n* Past hysterectomy with cervical removal\n* Known infection with HIV (as screening recommendations for people with HIV differ from the general population)\n* Inability to consent (e.g., lacking decisional capacity, intoxicated, or in distress)\n* Current pregnancy or in the three months after giving birth\n* Use of vaginal ovules, creams or washes, vaginal contraceptives or condoms within past 3 days\n* Sexual intercourse or transvaginal ultrasound scans or gynecological examinations within past 2 days",true,"30 Years","65 Years",{"count":84,"type":20},200,[56],"This project will compare the uptake of cervical cancer screening through ED HPV sampling among patients presenting to the ED.",[88,30,89,90,91],"HPV","HPV Cancers","Cervical Cancer Screening","Cervical Cancer (Early Detection)",[93,94,88,95],"HPV Screening","Cervical cancer screening","Cervical cancer","RECRUITING","2026-04-27",{"date":63,"type":36},{"date":100,"type":36},"2026-02-13",{"date":102,"type":20},"2028-01",{"name":104,"class":43},"University of Rochester",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":82,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100599875","phase-2-testing-for-safety-and-immune-effects-of-pds0101-an-anti-hpv-therapy-among-people-living-with-hiv-100599875","NCT07090174","Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV","A Single-Arm, Open-Label Clinical Phase II Trial of the Safety and Immunogenicity of PDS0101 in People Living With HIV","Inclusion Criteria:\n\n* HPV 16 detected on anal swab, cervical swab or vaginal swab ≤90 days of registration. (Note: HPV 16 detected on this swab can be from the screening evaluation or through standard of care assessments. The HPV 16 assay must be FDA-cleared and report HPV 16 results separately. The assay must be performed in a CLIA-certified laboratory.)\n* Cervical HSIL cohort: CIN III\u002Fcarcinoma in situ (CIS), CIN II\u002FIII, or CIN II with positive p16 stain diagnosed on cervical biopsy ≤90 days of registration and detection of cervical or vaginal HPV 16.\n* Cervical HSIL cohort: HSIL must occupy \\\u003C50% circumference of the cervical squamocolumnar junction, and adequate colposcopy with visualization of the endocervical HSIL margins. (Note: Participants with cervical HSIL occupying ≥50% of the circumference of cervical squamocolumnar junction and\u002For inadequate visualization of the endocervical HSIL margins are not eligible for this protocol.)\n* Anal HSIL cohort: anal intraepithelial neoplasia (AIN) III, AIN II\u002FIII, or AIN II with positive p16 stain diagnosed on anal or perianal biopsy ≤90 days of registration and detection of anal HPV 16.\n* Anal HSIL cohort: HSIL must occupy \\\u003C50% circumference of the squamocolumnar junction. (Note: Participants with anal HSIL occupying ≥50% of the circumference of cervical squamocolumnar junction are not eligible for this protocol.)\n* Ages 25-65 years (i.e., no longer eligible on the 66th birthday).\n* HIV infection with receipt of antiretroviral therapy for at least 12 months.\n* CD4+ T-cell count ≥200 cells\u002Fmm3 ≤45 days of registration.\n* Plasma HIV-1 RNA \\\u003C200 copies\u002FmL ≤45 days of registration.\n* Participants must meet the following laboratory parameters ≤45 days before enrollment:\n\n  1. Absolute neutrophil count: ≥1,500\u002Fmm3\n  2. Platelets: ≥100,000\u002Fmm3\n  3. Hemoglobin \\>12.5 g\u002FdL for men and \\>11.5 g\u002FdL for women\n  4. Estimated glomerular filtration rate (eGFR) \\>70 mL\u002Fmin\u002F1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation or serum creatinine \\\u003C1.2 x upper limit of normal (ULN)\n  5. Aspartate aminotransferase (AST) (SGOT), and alanine aminotransferase (ALT) (SGPT), \\\u003C1.5 x ULN\n  6. Total bilirubin \\\u003C1.5 x ULN\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (or Karnofsky ≥70%).\n* Willingness to comply with three-dose immunotherapeutic agent schedule and subsequent study visits.\n* The effects of PDS0101 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception prior to study entry and for at least 120 days after the last dose of study treatment. Women of childbearing potential must have a negative urine pregnancy test (β-human chorionic gonadotropin) within 24 hours prior to registration and prior to visits on Days 1, 22, 43, 57, and 127. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately and will not receive any additional doses of immunotherapeutic agent. Women who become pregnant and partners of male participants who become pregnant will be followed to assess pregnancy outcomes.\n* Ability to understand and the willingness to sign a written informed consent form (ICF).\n\nExclusion Criteria:\n\n* AIDS-defining condition within 6 months prior to study entry.\n* Receipt of blood products within 6 months of enrollment or are currently taking immune suppressants.\n* History of HPV-related cancer or suspected cancer of the cervix, anus, vagina, vulva, penis, or oropharynx.\n* Current diagnosis of cancer or prior invasive cancer \\> T1 stage (other than non-melanoma skin cancer) that has required active treatment within the past 3 years.\n* Suspicion of invasive cancer of the cervix, vulva, vagina, perianus or anal canal. (Note: Concomitant vulvar, vaginal, or perianal HSIL is not exclusionary.)\n* Surgical or ablative treatment for anal or cervical HSIL within 180 days of study entry.\n* Prior receipt of any doses of a licensed or experimental HPV immunotherapeutic agent. (Note: Prior receipt of licensed prophylactic HPV vaccines is permitted.)\n* Planned use of intravaginal, vulvar, perianal or intra-anal imiquimod or 5-fluorouracil or another topical therapeutic agent with possible activity against HPV disease, or their use within ≤90 days of entry.\n* Receipt of a live vaccine within 30 days prior to the first dose of treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Coordination and timing of COVID-19 vaccination should be based on local Investigator clinical assessment and judgment.\n* Received immunotherapy\u002Fimmunomodulatory or immunosuppressive agents (e.g., IFNs, tumor necrosis factor, interleukins, immunoglobulins or other biological response modifiers \\[GM-CSF, granulocyte-macrophage colony-stimulating factor\\]) within 6 weeks prior to administration of the first study treatment.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 30 days prior to the first dose of study treatment. (Note: Participants who entered the follow-up phase of an investigational study may participate as long as it has been 30 days after the last dose of the previous investigational agent.)\n* Is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Current or recent use of intra-articular, topical, or inhaled corticosteroids is acceptable.\n* Participants known to be positive for Hepatitis B antigen (HBsAg)\u002FHepatitis B virus (HBV) DNA or active Hepatitis C. Active Hepatitis C (HCV) is defined by a known positive HCV antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.\n* Plan to relocate during study period.\n* Acute medical conditions that would require exclusion from participation based on the opinion of the supervising physician.\n* Potential participants receiving any other investigational agents may be excluded in the opinion of the supervising physician.\n* Use of opioids within 2 weeks prior to enrollment. (Note: Medically assisted therapy for opioid use disorder or alcohol use disorder (e.g., stable methadone or buprenorphine\u002Fnaloxone) are not exclusionary. The rationale for excluding other opioid use is to allow appropriate grading of injection-related pain.)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. Current bacterial sexually transmitted infection (STI) requiring treatment (participants may participate after adequate treatment, at the discretion of the treating provider).\n* Pregnant or breastfeeding, unwilling\u002Funable to use contraception, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of any study treatment.\n\n  a) For the purpose of this study, a WOCBP (i.e., fertile) is defined as the period following menarche and until becoming post-menopausal unless permanently sterile. Acceptable methods of birth control for this study include: i) Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n\nii) A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n\niii) Use of a barrier (diaphragm or condom) with spermicide iv) Combined hormonal (estrogen and progestogen) contraception associated with inhibition of ovulation v) An intrauterine device\u002Fsystem vi. An oral, transdermal, or injectable contraceptive vii. A vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success.\n\nb) For the purpose of this study, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.\n\ni. Male participants must agree to use a condom as an effective method of contraception throughout the study and for at least 120 days after the last dose of study treatment.\n\n* Use of anticoagulants other than non-steroidal anti-inflammatory drugs or aspirin.",{"count":113,"type":20},27,[24],"This study is testing the immunotherapeutic agent, PDS0101, in adults living with HIV who are also infected with human papillomavirus (HPV) type 16. The purpose of the study is to learn whether PDS0101 is safe and whether it can help the body's immune system respond to HPV 16. Researchers will enroll 27 adults between the ages of 25 and 65 who have been receiving antiretroviral therapy (ART) for at least 12 months, have a cluster of differentiation 4 (CD4) cell count of at least 200 cells\u002Fmm³, and have an HIV viral load below 200 copies\u002FmL. All participants must have HPV 16 detected in the cervix, vagina, or anus. Some participants will have high-grade squamous intraepithelial lesions (HSIL), a condition that can lead to cancer. At least 10 participants will have cervical HSIL, and at least 10 will have anal HSIL. Participants with both cervical and anal HSIL will count in both groups. Others may have HPV 16 without HSIL.\n\nThis is a single-arm, open-label trial, which means that all participants will receive the same treatment, and both the investigators and the participants will know what the treatment is. Each participant will receive three doses of the PDS0101 vaccine. Participants who receive at least one dose will be included in the study's main safety analysis. If a participant does not receive all three doses and does not experience a serious side effect related to the vaccine (defined as a Grade 3 or higher toxicity), that participant may be replaced to make sure that 27 participants either complete the full vaccination schedule or experience a primary safety event. Participants who do have a qualifying safety event will not be replaced. Even if someone stops the study early, their data will still be included in the final analysis.\n\nThe main goals of this study are to evaluate the safety of PDS0101 and to measure the immune response it produces. The safety evaluation includes monitoring for serious or unexpected side effects, especially those that are Grade 3 or higher in severity. The immune response will be assessed by looking at how the body's T cells respond to HPV 16 after PDS0101 administration. The total time a participant is involved in the study includes the PDS0101 administration period and several follow-up visits, which may take place over the course of several months. This research may help inform future strategies for preventing or treating HPV-related disease in people living with HIV.",[30,117,118,60,119],"HIV (Human Immunodeficiency Virus)","Anal Cancer","HPV 16 Infection","2025-09-25",{"date":122,"type":36},"2025-10-01",{"date":124,"type":20},"2025-10-20",{"date":126,"type":20},"2026-07-31",{"name":128,"class":43},"Weill Medical College of Cornell University",3,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100574428","phase-2-phase-ii-clinical-trial-of-de-intensified-therapy-in-human-papilloma-virus-hpv-associated-oropharyngeal-squamous-cell-carcinoma-100574428","NCT06759155","Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically confirmed or suspected HPV associated squamous cell carcinoma of the oropharynx.\n* p16 immunohistochemistry is the surrogate marker for HPV positivity and will be scored as positive if there is strong and diffuse nuclear and cytoplasmic staining present in greater than 70% of the tumor specimen. (A negative result excludes the patient from the trial)\n* In the case of equivocal p16, High Risk HPV (HR HPV), In-Situ Hybridization (ISH) \u002F Polymerase Chain Reaction (PCR) may be performed to determine HPV positivity\n* AJCC TNM 7th edition stage T1-T3, N0-N2b (or AJCC TNM 8th edition stage T1-T3 N0-N1) disease.\n* Staging will be based on cross sectional imaging investigations and clinical exam.\n* Patients who initially have an unknown primary but subsequently have a primary site identified on pathology after surgical resection may be included in the study.\n* Multidisciplinary team decision to treat with primary transoral resection and neck dissection.\n* Patients considered fit for surgery and adjuvant therapy.\n* Aged 18 or over.\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* HPV negative squamous cell carcinomas of the head and neck\n* T4 and\u002For T1-T3 tumors where transoral surgery is considered not feasible or there is a high likelihood of positive margins.\n* AJCC TNM 7th edition N2c-N3 nodal disease (or AJCC TNM 8th edition N2-N3 nodal disease) or high likelihood of gross extranodal extension.\n* Patients for whom transoral surgery and neck dissection is not considered the primary treatment modality.\n* Distant metastatic disease as determined by routine pre-operative staging radiological investigations e.g. CT thorax and upper abdomen or PET CT.\n* Women who are pregnant or breastfeeding\n* Prior history of radiation to head and neck",{"count":137,"type":20},20,[24],"HPV-associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a type of cancer that affects parts of the throat, like the tonsils and the base of the tongue. The treatments for OPSCC, which may include surgery, radiation, and chemotherapy, often cause serious side effects, such as loss of taste, dry mouth, and long-term problems with swallowing. These side effects can lower patients' quality of life and make it difficult for them to eat and speak normally.\n\nThis study aims to explore whether using lower doses of radiation after surgery can help improve long-term swallowing function in patients with HPV-positive OPSCC. By doing this, the study team hopes to reduce treatment-related side effects while maintaining good cancer control.",[141,142,30],"OPSCC","Oropharyngeal Squamous Cell Carcinoma (SCC)",[144,145],"radiation","de-intensify","2024-12-27",{"date":148,"type":36},"2025-01-06",{"date":150,"type":20},"2025-01",{"date":152,"type":20},"2030-01",{"name":154,"class":43},"University of Vermont Medical Center","HPV-Associated Cancers"]